Status:
COMPLETED
Rasburicase in Tumor Lysis Syndrome
Lead Sponsor:
Sanofi
Conditions:
Hyperuricemia
Eligibility:
All Genders
Up to 18 years
Phase:
PHASE4
Brief Summary
The purpose of this study is to determine whether rasburicase is effective and safety in correcting hyperuricemia.
Eligibility Criteria
Inclusion
- List of inclusion Criteria:
- Acute hyperuricemia patients(uric acid\>8.0 mg/dl) before/during chemotherapy for hematologic malignancies.
- List of exclusion Criteria:
- Hypersensitivity to uricases or any of the excipients.
- Known history of hemolytic anemia (G6PD deficiency).
- The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Exclusion
Key Trial Info
Start Date :
February 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
33 Patients enrolled
Trial Details
Trial ID
NCT00302653
Start Date
February 1 2006
Last Update
September 25 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sanofi-aventis administrative office
São Paulo, Brazil